This OPO is graded Tier 3 (2023 Assessment (CY2021 data)) under the CMS Conditions for Coverage outcome measures. Tier 3 is below the median on a required measure — the band CMS deems out of compliance and eligible for decertification.
A university tissue bank spun out a for-profit processor that became a public company
RTI Surgical (originally Regeneration Technologies, Inc.), from University of Florida Tissue Bank
In February 1998 the University of Florida Tissue Bank transferred its allograft processing operations, equipment, technologies and distribution arrangements to Regeneration Technologies, Inc. The company completed an initial public offering in August 2000 and traded on NASDAQ under the symbol RTIX, later becoming RTI Biologics and then RTI Surgical through mergers and acquisitions — a documented path from nonprofit/university tissue bank to publicly traded for-profit processor.
Every item is institution-level public record, source-linked; no patient, donor, or family is named. A Tier or finding here repeats the government's own assessment of an organization holding a public monopoly. Back to OrganWatch.